What is Solarea Bio?
Solarea Bio is a biotechnology firm headquartered in Cambridge, Massachusetts, dedicated to pioneering microbiome-based solutions for critical global health issues. Established in 2017 by a consortium of scientists and entrepreneurs, the company aims to revolutionize the understanding and application of the human microbiome for enhanced health outcomes. Solarea Bio's foundational breakthrough involved identifying a novel source of probiotic microorganisms within healthy foods and establishing their therapeutic potential, particularly in managing inflammatory processes such as the gut-musculoskeletal axis.
How much funding has Solarea Bio raised?
Solarea Bio has raised a total of $26.2M across 2 funding rounds:
Series A
$11.2M
Series B
$15M
Series A (2020): $11.2M with participation from BOLD Capital Partners, S2G Ventures, Viking Global Investors, and Gisev Family Office
Series B (2023): $15M led by Viking Global Investors, S2G Ventures, and BOLD Capital Partners
Key Investors in Solarea Bio
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies.
S2G Ventures
S2G Ventures (Seed 2 Growth) is a multi-stage food and agriculture venture fund investing in entrepreneurs whose products and services meet the shifting demands for healthy and sustainable food. S2G looks for companies that can take leadership positions in emerging and fast growing markets in the food and agriculture sector.
BOLD Capital Partners
BOLD Capital Partners is a venture capital firm dedicated to investing in entrepreneurs and technologies that aim to transform the world, focusing on emerging science and technologies that can disrupt large markets.
What's next for Solarea Bio?
With its recent major strategic investment, Solarea Bio is poised for accelerated growth and the scaling of its innovative microbiome therapies. The substantial backing from investors like Viking Global Investors, S2G Ventures, and BOLD Capital Partners signals a strong market validation for the company's scientific advancements. This capital infusion will likely fuel further research and development, clinical trials, and the expansion of its product pipeline, positioning Solarea Bio to make a significant impact on human health by harnessing the power of the microbiome.
See full Solarea Bio company page
